

PTO/SB/17 (01-06)

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

**FEE TRANSMITTAL**  
**For FY 2006**☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$180)**Complete if Known**

Application Number	10/821,573
Filing Date	April 8, 2004
First Named Inventor	Gilbert, Michel
Examiner Name	Sheridan Swope
Art Unit	1656
Attorney Docket No.	019633-000128US

**METHOD OF PAYMENT (check all that apply)**

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): \_\_\_\_\_  
☒ Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17☒ Credit any overpayments**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**FEE CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.)****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Small Entity	Fee (\$)	Small Entity	Fee (\$)	Small Entity	Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

**2. EXCESS CLAIM FEES****Fee Description**

Each claim over 20 (including Reissues)

Each independent claim over 3 (including Reissues)

Multiple dependent claims

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
--------------	--------------	----------	---------------

\_\_\_\_\_ -20 or HP = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_  
HP = highest number of total claims paid for, if greater than 20

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
---------------	--------------	----------	---------------

\_\_\_\_\_ -3 or HP = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_  
HP = highest number of independent claims paid for, if greater than 3

Small Entity	Fee (\$)
50	25
200	100
360	180

**Multiple Dependent Claims**

Fee (\$)	Fee Paid (\$)
----------	---------------

**3. APPLICATION SIZE FEE**

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
_____	_____	_____ / 50 = _____ (round up to a whole number)	x _____	_____

**4. OTHER FEE(S)**

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Submission of Information Disclosure Stmt

180

**SUBMITTED BY**

Signature

Name (Print/Type)

Beth L. Kelly

Registration No. 51,868  
(Attorney/Agent)

Telephone 415-576-0200

Date 08/18/2006

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On

TOWNSEND and TOWNSEND and CREW LLP

PATENT  
Attorney Docket No.: 019633-000128US  
Client Reference No.: NRC00072.1D1C6,  
NRC IPSO 11382



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

GILBERT and WAKARCHUK

Application No.: 10/821,573

Filed: April 8, 2004

For: SIALYLTRANSFERASES FROM  
C. JEJUNI

Confirmation No.: 2448

Examiner: Sheridan Swope

Art Unit: 1656

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 10/303,128, filed November 21, 2002 (Attorney Docket No. 019633-000112US).

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

08/23/2006 DENMANU1 00000024 201430 10821573

02 FC:1806

180.00 DA


GILBERT and WAKARCHUK  
Application No.: 10/821,573  
Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account..

Respectfully submitted,

  
Beth L. Kelly  
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
BLK:ath



PTO/SB/08A (07-05)

Substitute for Form PTO		Complete if Known	
		Application Number	10/821,573
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Filing Date	April 8, 2004
		First Named Inventor	Gilbert, Michel
		Art Unit	1656
		Examiner Name	Sheridan Swope
		Attorney Docket Number	019633-000128US
Sheet	1	of	3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,352,670	10-04-1994	Venot, et al.	
	AB	5,374,541	12-20-1994	Wong, et al.	
	AC	5,545,553	08-13-1996	Gotschlich	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AD	WO	92/16640		10-01-1992	The Scripps Research Institute		<input type="checkbox"/>
	AE	WO	96/32491		10-17-1996	Cytel Corp.		<input type="checkbox"/>
	AF	WO	99/49051	A1	09-30-1999	National Research Council of Canada		<input type="checkbox"/>
	AG	WO	00/46379	A1	08-10-2000	National Research Council of Canada		<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/821,573
				Filing Date	April 8, 2004
				First Named Inventor	Gilbert, Michel
				Art Unit	1656
				Examiner Name	Sheridan Swope
Sheet	2	of	4	Attorney Docket Number	019633-000128US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AH	ASPINALL et al., "Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Structures of Core Oligosaccharide Regions from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome" Biochemistry, 33: 241-249 (1994b)	<input type="checkbox"/>
	AI	ASPINALL et al., "Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Antigen Chains from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome" Biochemistry, 33: 250-255 (1994c)	
	AJ	ASPINALL, et al. " Chemical Structures of the Core Regions of Campylobacter Jejuni Serotypes O:1, O:4, O:23, and O:36 Lipopolysaccharides," European Journal of Biochemistry, Vol. 213, No. 3, pp. 1017-1027, (May 1993)	
	AK	ASPINALL, et al. "Lipopolysaccharides from Campylobacter Jejuni Associated with Guillain-Barré Syndrome Patients Mimic Human Gangliosides in Structure," Infection and Immunity, Vol. 62, No. 5, pp. 2122-2125, (May 1994)	
	AL	AUSUBEL et al. "Protein Expression" In: <u>Current Protocols in Molecular Biology</u> , Wiley and Sons, Inc. 1987, Chapter 16	
	AM	BELUNIS et al., "Biosynthesis of Endotoxin" J. Biol. Chem., 267: 9988-9997 (1992)	
	AN	GAUDINO et al., "A Novel and Efficient Synthesis of Neolacto Series Gangliosides 3'-nLM1 and 6'-nLM1 " J. Am. Chem. Soc., 116: 1149-1150 (1994)	
	AO	GILBERT et al., "Cloning of the Lipooligosaccharide $\alpha$ -2,3-Sialyltransferase from the Bacterial Pathogens Neisseria Meningitidis and Neisseria Gonorrhoeae", Journal of Biological Chemistry, Vol. 271, No. 45, pp. 28271-28276, The American Society for Biochemistry and Molecular Biology, Inc., USA, (November 8, 1996)	
	AP	GILBERT, et al., "Biosynthesis of Ganglioside Mimics in Campylobacter Jejuni OH4384," The Journal of Biological Chemistry, Vol. 275, No. 6, pp. 3896-3906, The American Society for Biochemistry and Molecular Biology, Inc., USA, (February 11, 2000)	
	AQ	ITO et al., "Synthesis of Bioactive Sialosides" Pure Appl. Chem., 65: 753 (1993)	
	AR	KUROKI, "Campylobacter jejuni Strains from Patients with Guillain-Barré Syndrome Belong Mostly to Penner Serogroup 19 Contain $\beta$ -N-Acetylglucosamine Residues" Ann. Neurol., 33: 243-247 (1993)	
	AS	PARKHILL, et al. "The Genome Sequence of the Food-Borne Pathogen Campylobacter Jejuni Reveals Hypervariable Sequences," Nature, Vol. 403, pp. 665-668, (February 10, 2000)	
Examiner Signature			Date Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/821,573
				Filing Date	April 8, 2004
				First Named Inventor	Gilbert, Michel
				Art Unit	1656
				Examiner Name	Sheridan Swope
Sheet	3	of	4	Attorney Docket Number	019633-000128US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s); volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	AT	PENNER, et al., "Diversity of Lipopolysaccharide Structures in Campylobacter Jejuni," The Journal of Infectious Diseases, Vol. 176, No. 2, pp. S135-S138, (December 1997)		
	AU	PRENDERGAST, et al., "Lipopolysaccharides form Campylobacter Jejuni O:41 Strains Associated with Guillain-Barré Syndrome Exhibit Mimicry of GM1 Ganglioside," Infection and Immunity, Vol. 66, No. 8, pp. 3649-3677, (August 1998)		
	AV	PRESTON, et al., "The Lipooligosaccharides of Pathogenic Gram-Negative Bacteria," Critical Reviews in Microbiology, Vol. 22, No. 3, pp. 139-180, (1996)		
	AW	SABESAN et al., "Combined Chemical and Enzymatic Synthesis of Sialyloligosaccharides and Characterization by 500-MHz 1H and C NMR Spectroscopy" J. Am. Chem. Soc., 108: 2068-2080 (1986)		
	AX	SALLOWAY, et al., "Miller-Fisher Syndrome Associated with Campylobacter Jejuni Bearing Lipopolysaccharide Molecules that Mimic Human Ganglioside GD3," Infection and Immunity, Vol. 64, No. 8, pp. 2945-2949, (August 1996)		
	AY	TOMB et al., "The complete genome sequence of the gastric pathogen <i>Helicobacter pylori</i> ", Swiss-Prot Accession No.: A64547, Alignment with SEQ ID NO:17		
	AZ	WAKARCHUK et al., "Functional Relationships of the Genetic Locus Encoding the Glycosyltransferase Enzymes Involved in Expression of the Lacto-N-neotetraose Terminal Lipopolysaccharide Structure in <i>Neisseria meningitidis</i> " J. Biol. Chem., 271: 19166-19173 (1996)		
	BA	WOOD, et al., "Cloning, Mutation and Distribution of a Putative Lipopolysaccharide Biosynthesis Locus in Campylobacter Jejuni," Microbiology, Vol. 145, No. 2, pp. 379-388, (February 1999)		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.